Related Experiment Video
Updated: Jun 16, 2026
13:13
Biochemical Measurement of Neonatal Hypoxia
Published on: August 24, 2011
Predicting neonatal hyperbilirubinemia using first day serum bilirubin levels
Shivani Randev1, Neelam Grover
1Department of Pediatrics, Indira Gandhi Medical College, Shimla, India. shivanirandev16@rediffmail.com
Indian Journal of Pediatrics
|January 29, 2010
Summary
A first-day total serum bilirubin (TSB) level below 6.4 mg/dl reliably predicts a low risk of significant hyperbilirubinemia in newborns. This screening test aids in identifying neonates needing further monitoring for jaundice.
Area of Science:
- Neonatal Medicine
- Pediatrics
- Clinical Chemistry
Background:
- Hyperbilirubinemia is a common condition in newborns, requiring careful monitoring.
- Predicting significant hyperbilirubinemia early is crucial for timely intervention and preventing complications.
Purpose of the Study:
- To identify a predictive first-day total serum bilirubin (TSB) threshold for neonates at risk of developing significant hyperbilirubinemia.
Main Methods:
- Serum bilirubin was measured in 200 neonates within 18-30 hours of life.
- Infants were clinically assessed for jaundice progression, with TSB re-estimation if needed.
- Hyperbilirubinemia was defined by specific TSB levels at different postnatal age intervals.
Main Results:
- 12% of neonates developed hyperbilirubinemia.
- The mean first-day TSB was significantly higher in neonates who developed hyperbilirubinemia (7.716 mg/dl) versus those who did not (5.154 mg/dl).
- A first-day TSB of 6.4 mg/dl demonstrated optimal prediction (87.5% sensitivity, 80.11% specificity) for subsequent hyperbilirubinemia.
Conclusions:
- First-day TSB measurement is a reliable screening tool for identifying neonates at risk of hyperbilirubinemia.
- Newborns with a first-day TSB below 6.4 mg/dl have a minimal risk of developing significant hyperbilirubinemia.
Related Concept Videos
01:25Jaundice
Jaundice, or icterus, is the yellow discoloration of the skin, sclerae, and mucous membranes. It happens when plasma bilirubin levels rise above 2.5-3 mg/dL, leading to bilirubin deposition in tissue.Bilirubin is a byproduct of hemoglobin degradation. In macrophages, hemoglobin breaks down into globin and heme. Globin is converted into amino acids, while heme is turned into biliverdin by heme oxygenase, which is then reduced to unconjugated bilirubin by biliverdin reductase.Unconjugated...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...